Mutated Arylsulfatase A for Sulfatide Clearance in MLD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for metachromatic leukodystrophy (MLD), such as enzyme replacement therapy (ERT) and gene therapy, face challenges in delivering sufficient arylsulfatase A (ARSA) enzyme activity to the central nervous system due to the blood-brain barrier, requiring high doses that can induce adverse effects and enzyme inefficiencies.
Innovation Solution
Development of a mutated ARSA enzyme with increased catalytic activity, allowing for lower enzyme concentrations and expressions while maintaining effective sulfatide metabolism, overcoming limitations of ERT and gene therapy by enhancing enzyme efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of wild-type ARSA enzyme are administered to overcome the blood-brain barrier, then sufficient enzyme activity can be delivered to the central nervous system, but adverse effects and enzyme inefficiencies are induced
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of the ARSA enzyme to create mutant variants with enhanced catalytic activity. Specific mutations (e.g., M202V, T286L, R291N) alter the enzyme's parameters to achieve up to 5-fold increased activity, allowing effective sulfatide metabolism at lower concentrations and reducing adverse effects associated with high-dose wild-type enzyme administration
2Reliability
If high doses of ARSA enzyme are administered to overcome the blood-brain barrier, then sufficient enzyme activity can be delivered to the central nervous system, but enzyme inefficiencies occur
Solution Approach 1:
The patent improves enzyme efficiency by changing the kinetic parameters of the ARSA enzyme through targeted amino acid mutations. The mutant enzymes exhibit enhanced catalytic efficiency (kcat/Km) towards sulfatide substrates, enabling more effective sulfatide degradation at lower enzyme concentrations and avoiding the inefficiencies associated with supraphysiological doses of wild-type enzyme
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mutated ARSA enzyme achieves up to 5-fold increased activity compared to wild-type, effectively reducing sulfatide accumulation and neurological symptoms in MLD patients, with potential for prolonged therapeutic benefits and reduced adverse effects.
Implementation Method 1
ARSA hydrolyzes sulfatide to galactosylceramide and sulfate
Data Source
AI summary
The present invention pertains to a novel treatment of pathologies caused by an increased synthesis or accumulation of sulfolipids such as sulfatide. The invention provides mutated arylsulfatase A (ARSA or ASA, EC 3.1.6.8) enzymes with increased activity towards sulfatide metabolization. The invention provides nucleic acids encoding the mutant ARSA, the use of the proteins and nucleic acids, as well as pharmaceutical compositions comprising them, in the treatment of lysosomal storage disorders (LSDs) such as metachromatic leukodystrophy (MLD).